SENORES PHARMACEUTICALS L
SENORES · General/Diversified · NSE
₹891
Current Market Price
Fair Value (DCF)
₹356
Margin of Safety
-60.1%
Updated just now
YieldIQ Score
64/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
15%
ROE
—
Debt/Equity
0.29
WACC
11.1%
Market Cap
₹4,104 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
9.2%
Return on capital employed
EV / EBITDA
26.2×
Enterprise multiple
Debt / EBITDA
2.1×
Leverage vs earnings
Interest Coverage
4.5×
EBIT covers interest
Current Ratio
3.00×
Short-term liquidity
Asset Turnover
0.31×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹891.15
Bear case
₹207.49
MoS -329.5%
Base case
₹355.96
MoS -150.4%
Bull case
₹451.83
MoS -97.2%
Ratio Trends
SENORES · last 4 annual periods
ROE
7.2%
ROCE
9.6%
Operating Margin
—
Debt / Equity
0.39×
PE
—
EV / EBITDA
—
Historical Financials
SENORES · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹14.1 Cr | ₹35.3 Cr | ₹211 Cr | ₹383 Cr | +200.8% |
| EBITDA | ₹2.4 Cr | ₹16.1 Cr | ₹43.5 Cr | ₹108 Cr | +257.5% |
| EBIT | — | — | — | — | — |
| PAT | ₹1.0 Cr | ₹8.4 Cr | ₹31.4 Cr | ₹58.6 Cr | +289.5% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹-10.4 Cr | ₹-1.1 Cr | ₹-25.7 Cr | ₹-45.9 Cr | — |
| CapEx | ₹-10.7 Cr | ₹-47.3 Cr | ₹-51.8 Cr | ₹-158 Cr | — |
| FCF | ₹-21.1 Cr | ₹-48.4 Cr | ₹-77.5 Cr | ₹-203 Cr | — |
| Total Assets | ₹59.2 Cr | ₹131 Cr | ₹622 Cr | ₹1227 Cr | +174.8% |
| Total Debt | ₹14.8 Cr | ₹62.6 Cr | ₹258 Cr | ₹315 Cr | +177.3% |
| Shareholders' Equity | ₹36.6 Cr | ₹45.5 Cr | ₹232 Cr | ₹812 Cr | +181.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SENORES vs 4 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| SMSPHARMA SMSPHARMA | — | — | Pending | 10.8% | — |
| SAIPARENT SAIPARENT | — | — | Pending | 15.9% | — |
| NGLFINE NGLFINE | — | — | Pending | 7.5% | — |
| TTKHLTCARE TTKHLTCARE | — | — | Pending | 7.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SENORES in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SENORES →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SENORES →
Compare
Head-to-head with peers
Compare SENORES side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SENORESNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.